← Trials/Trial dossier/NCT05813795
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)
Lead sponsor
Asset
Ecnoglutide (XW003)
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
—
Enrollment
664
actual
Study population
Obesity / overweight
Key I/E criterion
•BMI 24-28
Primary endpoints
•Body weight, % change•≥5% weight-loss responders
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Male or female, 18-75 years old, inclusive;
2. BMI between 24.0 to 28.0 kg/m2 with at least one comorbidity, including prediabetes, hypertension, hyperlipidemia, fatty liver , obstructive sleep apnea syndrome, etc.; or BMI ≥ 28 kg/m2 with or without comorbidities.
3. Weight change of no more than 5% (based on self-report), with diet and exercise alone, within 3 months before screening.
4. Willing and able to maintain stable diet and exercise during the study period.
Exclusion criteria
1. Obesity induced by endocrine diseases such as hypothyroidism, Cushing Syndrome, etc.
2. History of bariatric surgery (except liposuction >1 year ago) or planned bariatric surgery during the study period.
3. Within 3 months before screening, history of using the following drugs or treatments:
1. Any approved or unapproved weight-loss drugs or Chinese herbs or health products that affect body weight.
2. Any hypoglycemic medication.
3. Any medication that may cause significant weight gain, including systemic glucocorticoid treatment, tricyclic anti-depressants, anti-epileptic and antipsychotics.
4. Any investigational drug, vaccine, or medical device.
Endpoints (6)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Weight & body composition
6 endpointsPercent change in body weight from baseline
Time frame:Week 40
Body weight, % change
percent change from baseline, improvement
Proportion of subjects with weight loss ≥5% from baseline
Time frame:Week 40
≥5% weight-loss responders
threshold achievement, improvement
Percent and absolute body weight change from baseline
Time frame:Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
change from baseline, improvement
Proportion of subjects with weight loss ≥ 5%, 10%, 15% from baseline
Time frame:Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
≥5% weight-loss responders
threshold achievement, improvement
Change from baseline in BMI
Time frame:Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
BMI, change
change from baseline, improvement
Change from baseline in waist and hip circumferences
Time frame:Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Waist circumference, change
change from baseline, improvement
Publications (1)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- The lancet. Diabetes & endocrinology2025 Sep (month)PMID40555243doi:10.1016/S2213-8587(25)00141-Xvia clinicaltrials gov reference derived + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.